Deep Track Capital, LP
Q4 2022 13F-HR Holdings
Net value change ($000)
+198,234
(9.1%)
New positions
13
Sold out positions
16
Turnover %
34.9%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IMVT | 117,333 | 213.3% |
| INSM | 85,201 | NEW |
| BIIB | 83,076 | NEW |
| SRPT | 68,450 | NEW |
| VRNA | 54,374 | 188.1% |
| IONS | 45,542 | NEW |
| IVERIC bio, Inc. | 43,091 | 34.3% |
| DICE Therapeutics, Inc. | 33,825 | 166.8% |
| 89bio, Inc. | 33,749 | 221.1% |
| FDMT | 33,309 | 129.6% |
Top Reduces (Value $000, Stocks/ETFs)
| NVCR | -98,300 | -100.0% |
| KURA | -43,522 | -100.0% |
| BMRN | -42,991 | -68.6% |
| AUPH | -41,293 | -96.7% |
| Horizon Therapeutics Public Ltd Co | -33,633 | -37.1% |
| FATE | -29,382 | -100.0% |
| NKTX | -28,931 | -78.1% |
| AKRO | -26,931 | -100.0% |
| Verve Therapeutics, Inc. | -26,621 | -100.0% |
| KALV | -26,466 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
87,826
(3.7% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|